Donna Reuter

Counsel

Overview

Leveraging her experiences as a practitioner in the healthcare industry, Donna capably serves clients with her industry experience and her commitment to achieving client goals.

Donna is a healthcare counsel in the Washington D.C. office, and her practice focuses on serving healthcare payer, provider, association, and industry clients in a broad array of legal matters spanning both litigation and regulatory compliance. She has previously worked on a variety of disputes involving areas of ERISA; medical malpractice; COVID-19; fraud, waste and abuse; intellectual property; and more.

Donna draws from her prior career as a pharmacist to inform her practice of the law: as a pharmacy manager for a major retail chain, and later as a clinical review pharmacist for a nationwide pharmacy benefit manager in Minnesota. She understands claims adjudication and billing processes, the pharmacy distribution chain, formulary management and utilization review processes, controlled substances laws, and pharmaceutical and healthcare adjacent areas.

In addition to her dedication to pro bono work, Donna enjoys mentoring, and is co-chair of the Minnesota Chapter of the Federal Bar Association’s quarterly newsletter, Bar Talk.

 

Career & Education

    • Mitchell Hamline School of Law, J.D., 2019
    • University of Minnesota, Pharm.D., 2011
    • California State University, Fresno, B.A., Mass Communication and Journalism, 2006
    • Mitchell Hamline School of Law, J.D., 2019
    • University of Minnesota, Pharm.D., 2011
    • California State University, Fresno, B.A., Mass Communication and Journalism, 2006
    • Minnesota
    • District of Columbia
    • U.S. District Court for the District of Minnesota
    • U.S. Court of Appeals for the Eighth Circuit
    • Minnesota
    • District of Columbia
    • U.S. District Court for the District of Minnesota
    • U.S. Court of Appeals for the Eighth Circuit

Donna's Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....

Practices

Donna's Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....